Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study.

Date publication

mai 2018

Journal

The Lancet. Respiratory medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr FALCOZ Pierre-Emmanuel , Pr OLLAND Anne

Tous les auteurs :
Warnecke G, Van Raemdonck D, Smith MA, Massard G, Kukreja J, Rea F, Loor G, De Robertis F, Nagendran J, Dhital KK, Moradiellos Díez FJ, Knosalla C, Bermudez CA, Tsui S, McCurry K, Wang IW, Deuse T, Lesèche G, Thomas P, Tudorache I, Kühn C, Avsar M, Wiegmann B, Sommer W, Neyrinck A, Schiavon M, Calebrese F, Santelmo N, Olland A, Falcoz PE, Simon AR, Varela A, Madsen JC, Hertz M, Haverich A, Ardehali A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29650408

Résumé

Severe primary graft dysfunction (PGD) of grade 3 (PGD3) is a common serious complication following lung transplantation. We aimed to assess physiological donor lung preservation using the Organ Care System (OCS) Lung device compared with cold static storage.

Mots clés

Adult, Cryopreservation, methods, Female, Humans, Lung Transplantation, adverse effects, Male, Middle Aged, Organ Preservation, instrumentation, Organ Preservation Solutions, Primary Graft Dysfunction, prevention & control, Prospective Studies, Risk Factors, Survival Analysis, Treatment Outcome

Référence

Lancet Respir Med. 2018 05;6(5):357-367